SCAN 2025 – NET patient survey (New Zealand)
The New Zealand reading of the global SCAN 2025 survey of neuroendocrine cancer patients and clinicians – how our care compares with the world.
SCAN (Survey on the Challenges faced by patients and clinicians Affected by NETs) is a global survey run every few years. In 2025, 110 New Zealand patients and 73 clinicians took part. The results show where New Zealand leads – free, nurse-led care and world-class PRRT access – and where we fall behind, on treatment delays and awareness of clinical trials.
View the interactive SCAN 2025 report, or download the full PDF.
Related resources
More like this →
MEN1 syndrome (Multiple Endocrine Neoplasia type 1)
MEN1 is a rare inherited condition that causes tumours in the endocrine glands – the parathyroids, pituitary and pancreas. What it is, what causes it, and how it is diagnosed.
BookletPatient Guide
This booklet has been developed to provide information about neuroendocrine tumours (NETs) for patients and their families.
Types of scans for NET Cancers
There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.
Grades of Neuroendocrine (NET) Cancers
What G1, G2 and G3 mean for a neuroendocrine cancer diagnosis – plain-language explanation of grade, Ki-67, and how they shape treatment options.